GAT564 (Compound 15d) is a highly effective allosteric modulator of cannabinoid 1 receptor (CB1R), having EC50 values of 87 nM and 320 nM for cAMP and β-arrestin2, respectively. It significantly enhances the binding of orthosteric ligands to hCB1R. Moreover, GAT564 exhibits remarkable efficacy as a topical agent, resulting in a significant reduction of intraocular pressure (IOP) in an ocular normotensive murine model of glaucoma [1].
(–)-IHCH7041 is a optical rotation negative isomer of IHCH7041. (–)-IHCH7041 is a DRD2 partial agonist. (–)-IHCH7041 showed EC50 = 1.38 nM in Gαi1–γ9 dissociation and 2.75 nM in β-arrestin2 recruitment. (–)-IHCH7041 exhibited a inhibition constant (Ki) of 22.44 nM binding affinity at DRD2. (–)-IHCH7041 has antidepressant properties and reverses cognitive impairment.
VUF14480 is a covalent partial agonist that interacts with cysteine 98(3.36) of the human histamine H₄ receptor. VUF14480 was shown to be a partial agonist of hH4 receptor-mediated G protein signalling and β-arrestin2 recruitment. VUF14480 bound covalently to the hH₄ receptor with submicromolar affinity. Serine substitution of C98(3.36) prevented this covalent interaction.